Spotting dementia risk early allows time for preventative measures, tailored care planning, and deeper research into the biological mechanisms driving the disease.

Study Overview: Long-Term Monitoring of Women

Researchers in the US analysed blood samples from 2,766 cognitively healthy women aged 65-79 in the 1990s. Their cognitive health was tracked over the following 25 years to see who developed mild cognitive impairment (MCI) or dementia.

Blood Biomarker Focus: p-tau217. The team measured levels of plasma phosphorylated tau 217 (p-tau217), a protein linked to tau tangles in the brain-a hallmark of Alzheimer's and other dementias. The full study has been published in JAMA Network Open, as reported byScience Alert

Why Blood Tests Matter

"Blood-based biomarkers like p-tau217 are promising because they are far less invasive and more accessible than brain scans or spinal fluid tests," says neuroscientist Linda McEvoy of the Kaiser Permanente Washington Health Research Institute. These tests could accelerate research and evaluate dementia risk-reduction strategies.

Key Findings: Association With Dementia Risk

Higher p-tau217 levels strongly correlated with an increased risk of MCI and dementia, though not all women with high levels developed the disease. This reinforces p-tau217 as a potentially useful biomarker.

Hormone Therapy and Risk

Among women on hormone therapy, higher p-tau217 predicted dementia in those taking combined estrogen and progestin, but not estrogen alone. No clear link was found between hormone therapy and MCI.

Racial Differences Observed

While elevated p-tau217 predicted dementia in both White and Black women, no association was seen with MCI in Black women. Researchers suggest this could be due to misdiagnosis, differing disease mechanisms, or demographic and health differences that were hard to fully control in the study.

Age and Genetic Factors

The link between higher p-tau217 and dementia was stronger in women over 70 and those carrying the APOE ε4 gene, known for its connection to Alzheimer's.

Next Steps for Screening

The p-tau217 blood test is not yet ready for general population screening. However, this research moves understanding of dementia's early development forward and highlights potential windows for intervention.

Expert Perspective

"Testing p-tau217 in blood could be a vital tool for identifying high-risk individuals years before diagnosis," says University of Oxford neurologist Masud Husain.

Future Implications

High p-tau217 levels don't always lead to dementia, suggesting areas for future research. Epidemiologist Aladdin Shadyab from the University of California, San Diego, notes, "Identifying at-risk women decades before symptoms appear opens the door to earlier prevention and targeted monitoring."

Disclaimer:This article is for informational purposes only and is not medical advice. Consult a healthcare professional for personal guidance.